Related Experiment Video
Updated: Nov 28, 2025

Assessment of Morphine-induced Hyperalgesia and Analgesic Tolerance in Mice Using Thermal and Mechanical Nociceptive Modalities
Published on: July 29, 2014
Multifunctional Opioid-Derived Hybrids in Neuropathic Pain: Preclinical Evidence, Ideas and Challenges
Joanna Starnowska-Sokół1,2, Barbara Przewłocka1
1Department of Pain Pharmacology, Maj Institute of Pharmacology, Polish Academy of Sciences, 31-343 Krakow, Poland.
Abstract:
When the first- and second-line therapeutics used to treat neuropathic pain (NP) fail to induce efficient analgesia-which is estimated to relate to more than half of the patients-opioid drugs are prescribed. Still, the pathological changes following the nerve tissue injury, i.a. pronociceptive neuropeptide systems activation, oppose the analgesic effects of opiates, enforcing the use of relatively high therapeutic doses in order to obtain satisfying pain relief. In parallel, the repeated use of opioid agonists is associated with burdensome adverse effects due to compensatory mechanisms that arise thereafter. Rational design of hybrid drugs, in which opioid ligands are combined with other pharmacophores that block the antiopioid action of pronociceptive systems, delivers the opportunity to ameliorate the NP-oriented opioid treatment via addressing neuropathological mechanisms shared both by NP and repeated exposition to opioids. Therewith, the new dually acting drugs, tailored for the specificity of NP, can gain in efficacy under nerve injury conditions and have an improved safety profile as compared to selective opioid agonists. The current review presents the latest ideas on opioid-comprising hybrid drugs designed to treat painful neuropathy, with focus on their biological action, as well as limitations and challenges related to this therapeutic approach.
Insights
New hybrid drugs combining opioids with other compounds show promise for treating neuropathic pain (NP). These dual-action therapies may improve efficacy and safety compared to traditional opioid agonists.
Area of Science:
- Pharmacology
- Neuroscience
- Drug Discovery
Background:
- Neuropathic pain (NP) affects over half of patients unresponsive to first- and second-line treatments.
- Opioid therapy for NP is often limited by pathological changes and adverse effects from compensatory mechanisms.
- Pronociceptive neuropeptide systems activation counteracts opioid analgesia, necessitating higher doses and increasing side effects.
Purpose of the Study:
- To review novel opioid-comprising hybrid drugs for neuropathic pain treatment.
- To explore the biological actions, limitations, and challenges of these dually acting therapeutic approaches.
- To highlight strategies for ameliorating NP treatment by addressing shared neuropathological mechanisms.
Main Methods:
- Literature review of recent advancements in hybrid drug design for neuropathic pain.
- Analysis of biological mechanisms underlying the efficacy and safety of opioid-based hybrid therapies.
- Examination of challenges in developing and implementing these novel treatments.
Main Results:
- Hybrid drugs combining opioid ligands with pharmacophores blocking anti-opioid actions offer a promising therapeutic strategy.
- These dually acting agents can target shared neuropathological mechanisms in NP and opioid exposure.
- Improved efficacy and safety profiles are anticipated compared to selective opioid agonists.
Conclusions:
- Opioid-comprising hybrid drugs represent a rational design approach to enhance neuropathic pain management.
- Addressing pronociceptive systems and opioid compensatory mechanisms is key to developing effective NP treatments.
- Further research and development are needed to overcome limitations and challenges in this therapeutic area.
Related Concept Videos
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Analgesia and Pain Management
Opioid Analgesics: Morphine and Other Natural Cogeners
Opioid Receptors: Overview
Nociception
Pain

